Dabigatran (Pradaxa)

Jules Comin, D. F. Kallmes

Research output: Contribution to journalShort surveypeer-review

7 Scopus citations


Dabigatran (Pradaxa) is a member of the relatively new class of antithrombotic drugs known as direct thrombin inhibitors (DTIs). It may supplant warfarin (Coumadin) in a number of applications as it may produce a more predictable, potent, and immediate anticoagulant effect, with fewer significant side effects and interactions, and requires less monitoring.

Original languageEnglish (US)
Pages (from-to)426-428
Number of pages3
JournalAmerican Journal of Neuroradiology
Issue number3
StatePublished - Mar 2012

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Clinical Neurology


Dive into the research topics of 'Dabigatran (Pradaxa)'. Together they form a unique fingerprint.

Cite this